…from a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
South San Francisco, Calif. and Cambridge, Mass. – August 28, 2006 – Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that a Phase II study of Rituxan ...
Press + Media
- Print Press Coverage
- TV Press Coverage
- Online Press Coverage
- Foundation Videos
- Foundation Blog
- Press Materials
Topics of Interest
Posted: Aug 04, 2014The two conditions share a surprising number of risk factors, but could one disease actually cause the ...
Posted: May 12, 2014Please join us for an opportunity to hear from our ...
Posted: Apr 07, 2014Please join us on May 2, 2014 at the Hyatt ...
Posted: Sep 24, 2013Taking place at the Hyatt Regency Century City on December ...